Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review

Abstract

Based on the findings from this review of real-world comparative effectiveness studies, risks of FN and FN-related complications were generally lower for prophylaxis with pegfilgrastim versus prophylaxis with short-acting G-CSFs.

The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge

“…Presently, there are two G-CSF types available on the market: the short-acting G-CSF, including filgrastim, tbo-filgrastim, filgrastim-sndz and lenograstim, and the pegylated long-acting one (pegfilgrastim and lipegfilgrastim). Pegfilgrastim was the first approved long-acting G-CSF product [10][11][12] • patient age > 65…”

“…However, studies comparing the efficacy of long-and short-acting G-CSF products indicate that a lower efficacy of the latter is often associated with an insufficient duration of their administration, i.e. from 3 to 7 days[12,19].g-csF ImPAct ON tHE EFFIcAcy OF cHEmOtHErAPyit has been demonstrated that G-CSF reduces the risk of febrile neutropenia, mortality related to infections, and the number of premature deaths[9,21].Dose-reducing toxicity, including myelotoxicity, is one of the chief factors impacting the efficacy of anti-cancer treatment[1][2][3][4]. intensified and prolonged neutropenia results in dose reduction and delayed administration of the consecutive cycles of chemotherapy, which in turn reduces its efficacy.…”

The importance of supportive care for patients with cancer

“…On recovery, subsequent chemotherapy doses could be reduced; however, this would diminish their efficacy when given with curative intent. The advent of the use of granulocyte colony‐stimulating factor, longer‐acting formulations and recombinant stem cell factor, given with chemotherapy, has significantly decreased the severity and duration of neutropenia, thereby reducing the chance of infection or hastening recovery 1 . With this strategy, the dose intensity of chemotherapy can be maintained.…”

The role of granulocyte colony‑stimulating factor in breast cancer development: A review

“…G-cSF can act as a mobilizer of hematopoietic progenitor stem cells in blood donors or cancer patients (10). Therefore, recombinant human G-cSF (rhG-cSF) is commonly used to prevent and treat febrile neutropenia and mucositis after chemotherapy and radiotherapy for cancer patients (11). However, recent studies have found that G-cSF plays a crucial role in tumorigenesis.…”